Andy C. Rawstron
- Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research 120
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments 55
- Chronic Myeloid Leukemia Treatments 15
- Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment 83
- Immunology top 0.5%
- Immunodeficiency and Autoimmune Disorders 60
- Oncology top 2%
- Cancer Treatment and Pharmacology 12
-
- Monoclonal and Polyclonal Antibodies Research 23
-
- Protein Degradation and Inhibitors 16
Andy C. Rawstron
187 papers receiving 7.2k citations
Peers
Comparison fields: 5 of 103
- Genetics 3.9k
- Hematology 3.0k
- Pathology and Forensic Medicine 3.0k
- Immunology 2.9k
- Oncology 1.6k
Countries citing papers authored by Andy C. Rawstron
This map shows the geographic impact of Andy C. Rawstron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy C. Rawstron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy C. Rawstron more than expected).
Fields of papers citing papers by Andy C. Rawstron
This network shows the impact of papers produced by Andy C. Rawstron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy C. Rawstron. The network helps show where Andy C. Rawstron may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Andy C. Rawstron, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2022 | 40 | |
| 5 | 2021 | 4 | |
| 6 | 2021 | 6 | |
| 7 | 2020 | 13 | |
| 8 | 2019 | 19 | |
| 9 | 2019 | 180 | |
| 10 | 2017 | 25 | |
| 11 | The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy. | 2017 | 4 |
| 12 | 2016 | 95 | |
| 13 | 2012 | 69 | |
| 14 | 2009 | 121 | |
| 15 | Report of the European Myeloma Network (EMN) workshop on multiparametric flow cytometry in multiple myeloma and related disorders | 2007 | 0 |
| 16 | Achieving a MRD negative response after alemtuzumab for CLL is the best predictor for prolonged survival | 2003 | 5 |
| 17 | 2000 | 111 | |
| 18 | 2000 | 7 | |
| 19 | 1998 | 7 | |
| 20 | 1997 | 23 |
About Andy C. Rawstron
Andy C. Rawstron is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Immunology and Oncology, having authored 196 papers that have together received 7.3k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (120 papers), Lymphoma Diagnosis and Treatment (83 papers), Immunodeficiency and Autoimmune Disorders (60 papers), Multiple Myeloma Research and Treatments (55 papers), Monoclonal and Polyclonal Antibodies Research (23 papers), Protein Degradation and Inhibitors (16 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Cancer Treatment and Pharmacology (12 papers). The work is most often cited by research in Genetics (3.9k citations), Hematology (3.0k citations), Pathology and Forensic Medicine (3.0k citations), Immunology (2.9k citations) and Oncology (1.6k citations). Andy C. Rawstron has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Peter Hillmen, Roger G. Owen, Gareth J. Morgan, Stephen J. Richards, Andrew Jack, Faith E. Davies, Ben Kennedy, Paul Emery, Edward M Vital and J. A. Child. Their work appears in journals such as Blood, British Journal of Haematology, Annals of the Rheumatic Diseases, Cytometry Part B Clinical Cytometry and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.